Future Treatments

A triple GIP, GLP-1, and glucagon receptor agonist. The first Phase 3 result (TRIUMPH-4, 2026) showed 28.7% average weight loss at 68 weeks — the highest weight loss ever recorded in a Phase 3 randomised controlled trial. The addition of glucagon receptor agonism on top of GIP and GLP-1 may further boost metabolic rate and fat burning beyond what dual agonists achieve.

A fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide 2.4 mg in a single weekly injection. Amylin is a hormone co-secreted with insulin that reduces appetite and slows gastric emptying — complementing GLP-1 action through a different pathway.

A single unimolecular drug that activates both GLP-1 and amylin receptors — hitting the same two targets as CagriSema but in a single molecule rather than two separate drugs combined. Both a weekly injection and a daily pill are being developed. Early data shows exceptional promise, with oral Phase 1 results exceeding oral semaglutide.

MariTide takes a completely different approach to other weight loss drugs. While tirzepatide activates the GIP receptor, MariTide blocks it — using the opposite strategy — while also activating GLP-1. This antibody-peptide conjugate (a different drug class entirely from small molecules or peptide injections) only needs to be injected once a month or less, which could be transformative for adherence.